In conclusion, our findings show that isolated gallic acid and its commercial standard are active against both stem/progenitor and differentiated CML cells and synergize with BCR::ABL1 TKIs through the inhibition of mitochondrial respiration and oncogenic signaling pathways. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.